# Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

> **NCT07756593** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 30 (estimated)

## Conditions studied

- Prostate Cancer
- Metastatic Prostate Cancer

## Interventions

- **BIOLOGICAL:** Sipuleucel-T
- **BIOLOGICAL:** N803

## Key facts

- **NCT ID:** NCT07756593
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-30
- **Primary completion:** 2029-04-14
- **Final completion:** 2031-01-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07756593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07756593, "Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07756593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*